Latest News

Phase 2b study of Psychedelic Compound BPL-003 Shows Rapid, Persistent, and Significant Improvement in Treatment Resistant Depression / image credit ©fyb/stock.adobe.com
Phase 2b Study of Psychedelic BPL-003 Shows Rapid, Persistent, and Significant Improvement in Treatment Resistant Depression

July 2nd 2025

A single dose of BPL-003 was associated with improved MADRS scores as early as day 2 that were durable through week 8; phase 3 planning is anticipated.

Late Life Mood Disorders Show Strong Association with Tau and Amyloid Pathology, Study Reveals
Late-Life Mood Disorders Show Strong Association with Tau and Amyloid Pathology, Study Reveals

June 13th 2025

Postpartum Hormonal Contraceptives Up Depression Risk by 50%: Daily Dose / image credit: ©New Africa/AdobeStock
Postpartum Hormonal Contraceptives Up Depression Risk by 50%: Daily Dose

June 4th 2025

Bringing PPD Screening to the Forefront of Maternal Health: A Q&A with Joy Baker, MD
Bringing PPD Screening to the Forefront of Maternal Health: A Q&A with Joy Baker, MD

June 3rd 2025

Novel 5-HT2A Agonist Achieves 94% Remission Rate in Phase 2a MDD Trial, With Rapid and Durable Efficacy  / image credit ©tomertu/stock.adobe.com
Novel 5-HT2A Agonist GM-2505 Achieves 94% Remission Rate in Phase 2a MDD Trial, With Rapid and Durable Efficacy

May 27th 2025

Latest CME Events & Activities

Southern California Psychiatry Conference

July 11-12, 2025

Register Now!

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

View More

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

View More

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

View More

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

View More

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

View More

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

View More

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

View More

Southern Florida Psychiatry Conference

November 21-22, 2025

Register Now!

Real Psychiatry 2026

January 23-24, 2026

View More

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

View More

Optimizing Care for Patients With Tardive Dyskinesia

View More

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

View More

More News

© 2025 MJH Life Sciences

All rights reserved.